pg-102
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT00787137)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CD40 inhibitor
Engagement of CD40 by PG102 induces formation of a dysfunctional CD40 signaling complex characterized by altered TNFR-associated factor (TRAF) recruitment and association, with resultant ineffective induction of kinase and transcription factor activation. Importantly for potential therapeutic applications, although PG102 did not inhibit CD154¿CD40 binding, it inhibited and prevented CD154-induced CD40 activation. ( Do not confuse with PG102, a water soluble extract from Actinidia arguta).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109475 ↗
Also known as
- pg102
- pg-102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00787137 | Phase 1 | Dec 1, 2008 | Institute of Rheumatology, Belgrade, Serbia, PanGenetics UK Limited |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Institute of Rheumatology, Belgrade, Serbia | Academic/Hospital | 1 | 0 | 1 | 2008 |
| PanGenetics UK Limited | For profit | 1 | 1 | 1 | 2008 |
2 organizations
Page 1 / 1